Arena has fallen 70 percent since Sept. 14, when Food and Drug Administration staff issued a report saying the drug, lorcaserin, may cause cancer and works only by a “slim margin.” A panel of advisers to the FDA said yesterday that the treatment doesn’t work well enough to justify risks when used long-term in overweight or obese people. While the FDA usually follows panel recommendations, it isn’t required to do so.
via bloomberg.com
No comments:
Post a Comment